-
2023-505772-30-00
5
2022-11-09
Melanoma
-
2023-507697-40-00
5
2021-07-05
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2024-511658-28-01
5
2021-04-06
primary sclerosing cholangitis
-
2024-512269-14-00
5
2020-01-27
GIant cell Arteritis
-
2024-515946-17-00
5
2019-07-22
Non Small Cell Lung Cancer
-
2024-514885-38-00
5
2019-07-11
severe forms of mucous membrane pemphigoid
-
2024-513728-40-00
5
2019-07-02
scheduled surgery for digestive cancer
-
2024-516048-24-00
4
2019-06-19
CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST
-
2023-508726-10-00
5
2018-03-28
Hepatocellular Carcinoma
-
2023-504820-24-00
5
2018-03-21
Neoadjuvant/Adjuvant treatment for participants with Resectable Stage
-
2023-509348-84-00
5
2015-04-27
Chronic Lymphocytic Leukemia
-
2024-518741-21-00
4
2014-12-23
colon cancer
-
2024-516996-34-00
5
2012-04-12
oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
-
2024-516687-28-00
5
2025-06-06
Patients with GPA and inadequate response to standard of care therapy
-
2024-513440-29-00
10
2025-06-25
Sickle cell disease vaso-occlusive crisis
-
2023-508395-11-00
4
2024-09-10
idiopathic pulmonary fibrosis
-
2023-506185-31-00
10
2024-07-18
Idiopathic pulmonary fibrosis (IPF)
-
2022-502899-23-00
5
2024-04-23
Hepatic Encephalopathy (OHE)
-
2023-504418-30-00
4
2023-10-24
Idiopathic Pulmonary Fibrosis
-
2024-516374-29-00
11
2023-04-18
Patients with excessive supraventricular ectopies or short atrial runs
-
2022-500905-42-00
3
2023-03-24
pancreatic ductal adenocarcinoma
-
2024-514761-19-00
5
2023-01-25
Idiopathic Pulmonary Fibrosis
-
2024-512803-37-00
5
2022-10-05
Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
-
2023-508485-15-00
5
2021-04-22
Subjects with documented STEMI, presenting with persistent ischemic ch